Abstract. Natural antisense transcripts (NATs) constitute a class of non-coding RNAs that have emerged as important regulators of gene expression. However, involvement of NATs in colorectal cancer (CRC) development has not been reported to date. In the present study, the up-and downregulation of NATs were investigated in human CRC for their possible involvement in CRC development. Total RNAs isolated from 51 CRC tissues, 9 corresponding noncancerous tissues and 19 liver metastatic tissues from surgically resected samples were subjected to expression analysis using a custom-microarray containing human sense/ antisense probes for ca. 21,000 genes. Comparing CRC tissues with non-cancerous tissues, we identified 415 NATs differentially expressed in CRC and non-cancerous tissues to a significant degree (p<0.001, fold change >4.0 or ≤4.0). When a hierarchical clustering was performed on CRC and non-cancerous samples using these 415 NATs, the samples were separately clustered. Principal component analysis with the same NATs showed clear separation of CRC and noncancerous samples using the first two principal components (PC1, 80%; PC2, 10%). To validate the expression results obtained from the microarray, the expressions of the 3 selected NATs were examined by strand-specific RT-qPCR, revealing that these expression profiles were consistent with those obtained from microarray analysis. In addition, the NAT expression patterns were found to be different between primary tumors with liver metastasis and those without liver metastasis. In conclusion, these findings taken together indicated that NATs indentified in the present study would be involved in CRC development as well as possibly in its metastasis.
Introduction
Colorectal cancer (CRC) is one of the most frequent cancers in the world. The American Cancer Society estimates that CRC was the third leading cause of cancer deaths in both men and women in 2009 (1) . In Japan, the prevalence of CRC patients has doubled in the past two decades, and CRC has been the second cause of death in neoplastic diseases (2) .
CRC is a heterogeneous disease arising from a complex series of molecular events. The evolution of normal colonic mucosa to a potentially invasive cancer via benign adenoma has been reported to be associated with a series of genetic events (3) . Molecular detection methods based on gene mutation for APC, p53 and K-ras, have been developed within the past two decades (4) . Despite the advent of these molecular markers, their usage is still limited for diagnosis of CRC, due to the fact that the CRC detection rate is not high enough for practical usage, indicating that additional factors should be involved in CRC development. Therefore, identification of additional molecular events involved in CRC development is essential for more accurate diagnosis of CRC including the precancerous state.
Since microarray technology has provided information on expression levels of thousands of genes in a single analysis, this technology is considered to provide new potential tool in finding diagnostic biomarkers and molecular targets (5, 6) . Several early studies succeeded in identifying genes expressed specifically in CRC, and, subsequently, many researchers have focused on investigating the expression of messenger RNAs, which encode proteins (5, (7) (8) (9) (10) .
In recent years, a large number of non-coding RNAs have been discovered. Although non-coding RNAs do not directly participate in protein synthesis, these RNAs have been demonstrated to be involved in gene regulation. Currently, non-coding RNAs are classified as various RNA species such as microRNA, Piwi-interacting RNA and antisense RNAs (11) (12) (13) . Among the non-coding RNA species, natural antisense transcripts (NATs) have been systematically identified in across mammalian species (14) , and global transcriptome analysis shows that up to 70% of transcripts have antisense partners and that perturbation of NATs can alter the expression of the sense gene (15) . Recently, NATs of p15 have been discovered to regulate the expression of p15 in leukemia cells through heterochromatin formation (16) . Furthermore, the differential expression between normal and malignant breast tissues was observed for many sense and antisense pairs (17) . However, a comprehensive NAT analysis using CRC samples has not been reported to date.
In the present study, the up-and down-regulation of NATs were investigated in human CRC for their possible involvement in CRC development. The expression profiles of NATs were determined using a custom microarray containing human sense/antisense probes for ca. 21,000 genes. Our objective here was to identify the up-and down-regulation of NATs in human CRC for their possible involvement in CRC development, and to explore biomarkers for CRC.
Materials and methods
Patients and samples. Surgical samples of 51 primary tumors, 9 corresponding adjacent non-cancerous colorectal tissues and 19 liver metastasis tumors were obtained from 68 CRC patients who underwent surgical resection from April 2006 to March 2009 at Tsukuba University Hospital (Tsukuba, Japan). None of the patients received radiation and/or chemotherapy before colorectal surgery. The main characteristics of the CRC cases are listed in Table I . Informed consent was obtained from all patients for the collection of specimens and the study protocol was approved by the hospital ethics committee. All samples were frozen in liquid nitrogen immediately after surgical resection and were stored at -80˚C until RNA extraction.
Total RNA extraction. Total RNA was isolated from frozen samples using Isogen reagent (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. Quality and concentration of the RNA were assessed with the NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE) according to the manufacturer's instructions. All RNA samples indicated 260/280 nm absorbance ratios of 1.8-2.0. The integrity of the RNA was monitored by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and an RNA 6000 Nano LabChip kit (Agilent Technologies). Based on the instruction of the Bioanalyzer, total RNAs thus obtained were selected for further analysis; i.e., microarray analysis and strand-specific RT-qPCR.
Probe design of custom-microarray. One of the downstream research steps of microarray gene expression analysis is to investigate gene expression sites in tissues using in situ hybridization, for which probe size should be empiricallỹ 120 nucleotides (nt) to obtain a satisfactory hybridization signal/noise ratio. Since the copy numbers of gene transcripts were shown to be different depending on the region of genes (18) , probe sequences for microarray and for in situ hybridization should be selected in the same region of genes in order to interpret the results of microarray in the combination of those of in situ hybridization. Therefore, 120 nt sequences were first selected from human ORF sequences (Build35) for probe of in situ hybridization (Genetyx, Tokyo, Japan). The selected sequences were confirmed to be unique in the human genomic sequence by blast analysis, and were then submitted to Agilent server (Agilent Technologies) to design 60 nt sequences from 120 nt sequences for microarray probes. The sense and antisense sequences of 60 nt sequences thus designed were arranged in an Agilent 44 K x 4 system (20882 ORFs: Agilent eArray Design ID = 19052 produced by Tsukuba GeneTech Lab., Tsukuba, Japan) (Agilent Technologies).
Microarray analysis. Cyanine 3 (Cy3)-labeled cDNA was synthesized from 10 μg total RNA of CRC and non-cancerous samples using a LabelStar Array kit (Qiagen, Valencia, CA), Cy3-dUTP (GE Healthcare, Fairfield, CT), and random nonamer primer. Agilent 44 K x 4 human sense/antisense custom microarray slides described above were hybridized with the Cy3-labeled cDNA (2 μg) in a hybridization solution prepared with an In Situ Hybridization Kit Plus (Agilent Technologies), following the manufacturer's instructions. The Cy3 fluorescence signal images on the slides were obtained by a DNA microarray scanner (Agilent Technologies), and processed using the Feature Extraction version 8.1 software based on the instruction from Agilent Technologies.
Gene expression profiles of the samples were analyzed using GeneSpring GX10 software (Agilent Technologies). The expression data were normalized to the 75 percentile of all values on that microarray, followed by normalization of the median expression level of all samples. Gene expression data, when classified as either flag-'Present' or flag-'Marginal' in >70% of all samples, were loaded into the software.
The expression profiles of the samples were compared using unpaired t-tests (with Bonferroni FWER correction for unequal variances) as described in Results. Two-dimensional hierarchical clustering was performed for the log-transformed data using centroid-linkage and with euclidean correlation as the similarity measure. Variation in multigene expression was compared by principal component analysis (PCA).
Strand-specific RT-qPCR. Total RNAs were used for RT-qPCR of antisense RNAs. In order to normalize the values of antisense RNAs among samples, EGFP RNA was mixed in total RNAs as described below.
An aliquot of each RNA sample was mixed with an amount of RNA fragment (218 nucleotides) synthesized from pEGFP-C1 vector (Invitrogen, Carlsbad, CA) to attain a final amount of 5x10 -5 pmol/10 μg total RNA (19) . These RNA mixtures were subjected to synthesis of the first-strand cDNA only from antisense RNAs using forward primer (Table II) , EGFP reverse primer, and Reverse Transcriptase (Promega, Madison, WI), according to the procedure recommended by Promega (20) . Then, the mixtures were incubated at 55˚C for 60 min. The resulting cDNAs were incubated at 99˚C for 5 min and at 37˚C for 60 min with RNase A to digest RNA.
To confirm whether the fragments amplified in the qPCR were derived from the target sequences, the fragments amplified with primer pairs for qPCR were electrophoresed Table I . Characteristics of human CRC cases analyzed by microarray analysis. 
AJCC, American Joint Committee on Cancer; UICC, International Union Against Cancer. pT, pathological staging of primary tumor; pN, pathological staging of regional lymph nodes; pM, pathological staging of distant metastasis; PT-Hep(-), primary tumor without liver metastasis; PT-Hep(+), primary tumor with liver metastasis; Hep, metastasized liver tumor.
- 
though 4% agarose gel to obtain their fragment size, and then subjected to direct sequence analysis using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA).
The first-strand cDNAs derived from antisense RNAs were then used as a template for quantitative PCR (qPCR) using SYBR Green Real-time PCR Master Mix Plus (Toyobo , Table III . The top 20 NATs differentially up-and down-regulated in CRC vs. non-cancerous tissues. 
-----------------------------------------------------------------------------------------------------
Osaka, Japan) and primer pair sets described in Table II . The qPCRs were performed using an Applied Biosystem 7500 Real-Time PCR system (Applied Biosystems) under the conditions of 1 min at 95˚C followed by 40 cycles each of 95˚C for 15 sec and 60˚C for 60 sec, following the procedure recommended by the manufacturer. In order to compare the PCR results, the values for antisense RNAs were normalized based on values of EGFP. The results of qPCR are presented as means ± standard errors of means (SEM) of the samples.
Results

Gene expression profiling of up-and down-regulated NATs between the CRC and non-cancerous groups.
Total RNAs isolated from 51 CRC tissues and 9 corresponding noncancerous tissues (Table I) were subjected to custom microarray containing human sense/antisense probes. Microarray analysis was performed as described in Materials and methods. When gene expression profiles in the CRC and non-cancerous groups were compared, 863 sense/antisense transcripts were identified as those with amounts of which showed a >4-fold difference between the two groups using an unpaired t-test (p<0.001). Among these transcripts, sense transcripts numbered 448, and NATs numbered 415. Among the sense transcripts, 181 showed a higher expression (FC>4.0) and 267 showed a lower expression (FC<-4.0) in the CRC group than in the non-cancerous group (data not shown). These findings for sense transcripts are not inconsistent with several earlier studies (5,7-10). However, since NATs have not yet been reported in CRC development, the up-and down-regulated NATs were further investigated in the present study. In NATs, 101 showed a higher expression (FC >4.0) and 314 showed a lower expression (FC<-4.0) in the CRC group than in the non-cancerous group (data not shown, available on request). The top 20 up-and down-regulated NATs are listed in Table III. A hierarchical cluster analysis was performed using individual values of the respective transcripts for samples. The results of the analysis are presented in Fig. 1A . The CRC and non-cancerous samples were clustered into two groups; i.e., 'CRC' and 'non-cancerous' groups except for two cases. When PCA with 415 NATs was performed, the CRC and non-cancerous samples were clearly separated using the first two principal components (contribution ratios of PC1 and PC2 were 80 and 10%, respectively) (Fig. 1B) . These results demonstrate that there is a significant difference in 415 NATs between the CRC and non-cancerous groups, and infer that a small number of transcripts would contribute to differentiate the cancerous and non-cancerous state.
RT-qPCR analysis of NATs in the CRC and non-cancerous samples. OR52E5, C6orf149, ERG, PLB1, LRRC24, SLC26A3,
and IGJ were randomly selected from the genes shown in Table III , and subjected to validation of the NATs amounts obtained in the microarray with RT-qPCR. Studies on NATs, including those for mice, have shown that NATs have been characterized with various initiation sites and termination sites. Therefore, NATs of the above selected genes were first examined as to whether the primer pairs designed produced unique-sized fragments in the RT-qPCR using total RNA of the one patient (patient 7). The examination revealed that LRRC24, SLC26A3, and IGJ produced unique-sized fragments; while OR52E5, C6orf149, ERG, and PLB1 produced multiplesized fragments (data not shown). The DNA fragments produced for NATs of LRRC24, SLC26A3, and IGJ were sequenced to confirm that the DNA fragments were derived from the respective NATs. The NATs of LRRC24, SLC26A3, and IGJ were then subjected to RT-qPCR to determine their amounts in the total RNA samples of randomly selected four patients (patients 7, 16, 18, and 23). As shown in the results of the RT-qPCR analysis in Fig. 2 , NAT amounts of SLC26A3, and IGJ were smaller in the CRC than in the noncancerous tissues of the patients, whereas the NAT amount of LRRC24 was larger in CRC than in the non-cancerous tissues. Although the NAT amount ratios of the CRC to non-cancerous tissues obtained by microarray analysis was consistently higher than those obtained by RT-qPCR, the observations obtained in the RT-qPCR were consistent with those in the microarray. Based on the fact that NATs were characterized with various initiation sites and termination sites, it might be inferred that some portion of the NAT did not encompass both primer sequences used for RT-qPCR.
Consequently, although the number of NATs and patients applied for comparison between the microarray and RTqPCR analyses was limited, it was judged that the results of the microarray analysis would reflect the NAT expression profiles in CRC and non-cancerous tissues.
Identification of NATs that distinguish primary tumors with liver metastasis from primary tumors without liver metastasis.
In order to examine NATs profiles in liver metastasis, we investigated NATs expression profiles between primary tumors without liver metastasis [PT-Hep(-)] and primary tumors with liver metastasis [PT-Hep(+)]. Two hundred and fifty-six NATs were identified as the transcripts, amounts of which showed a >2-fold difference between the two groups using an unpaired t-test (p<0.05). Of these NATs, 226 showed a higher expression (FC >2.0), and 30 showed a lower expression (FC <-2.0) in PT-Hep(+) group than in PT-Hep(-) group (data not shown, available on request). The top 10 up-and downregulated NATs are listed in Table IV . When a hierarchical cluster analysis was performed using individual values of the respective NATs for samples, no significant clustering was obtained in the viewpoint of metastasis of CRC (data not shown). When PCA with 226 NATs was performed, the CRC and non-cancerous samples were not clearly separated using the first two principal components (contribution ratios of PC1 and PC2 were 68 and 10%, respectively) (data not shown). Then, additional hierarchical cluster analysis was performed using mean values of the individual transcripts in the respective groups, revealing two major nodes (Fig. 3) : non-cancerous and cancerous. The cancerous node was branched off into the node of PT-Hep(-) and PT-Hep(+) clustered with its metastasized liver tumor (Hep).
Discussion
A large number of studies have been performed on the difference of gene expressions between cancerous and non-cancerous tissues to obtain biomarkers for diagnosis of cancer as well as to understand the cancer development mechanism. However, the vast majority of these studies has focused on the mRNA of genes (sense transcripts), with only a few focusing on antisense transcript in human clinical cancer tissues (17, 21) . In the present study, we performed, for the first time, a comprehensive analysis of NATs in the human CRC tissues and non-cancerous tissues, seeking biomarkers for CRC and a clue to understand CRC development.
By comparing gene expression profiles of CRC tissues with non-cancerous tissues, we identified 415 NATs differentially expressed between the CRC and non-cancerous tissues to a significant degree. Hierarchical clustering analysis and PCA clearly distinguished the gene profiles of CRC from those of non-cancerous tissues using these 415 NATs. Strand-specific RT-qPCRs of 3 selected NATs (SLC26A3, IGJ, LRRC24) have validated the results of microarray. As described in Results, 4 of the 7 NATs selected for the validation failed to give single fragments in the RT-qPCR. The reason for this failure could be interpreted as follows. The annealing Table IV . The top 10 NATs differentially up-and down-regulated in primary tumors with liver metastasis vs. primary tumors without liver metastasis. temperature of the primers to RNA in RT was not able to be raised to the optimum due to the nature of the reverse transcriptase, which allowed the amplification of fragments from RNA species other than the target species. The absolute NAT amount ratios of CRC to non-cancerous tissues for the 3 genes examined in the microarray were consistently larger than those in RT-qPCR. It might be inferred that since NATs have been demonstrated to have various transcription initiation and termination sites (20, 22) , a limited number of NAT molecules were reverse transcribed to cDNA using the primer pairs listed in Table II . To verify this inference, a large number of RNA molecules should be randomly sequenced to identify of the NATs related to the 3 genes using a next-gen sequencer.
We also identified 256 NATs whose amounts differed significantly between PT-Hep(+) and PT-Hep(-). However, only the hierarchical clustering using mean values of the individual transcripts in the respective groups could separate PT-Hep(+) and PT-Hep(-) as different groups, but other analyses including PCA provided unclear separation. These results may indicate that events leading to metastasis of the liver may not significantly affect the amounts. Since, in the present study, NAT amounts were measured for one region per gene, and since NAT amounts were indicated to be different depending on the region of a gene (18) , NATs of regions other than those examined might clearly distinguish the CRC with respect to metastasis.
Asymmetric strand specific analysis of gene expression was applied on 5 different human cell types to reveal the expression of NATs from 2900 to 6400 genes, suggesting that they are a fundamental component of gene regulation (23) . Interestingly, knockdown or blockade of NATs can have multiple outcomes, with the corresponding sense transcript concentration showing either an increase (discordant regulation) or a decrease (concordant regulation) (24) . These variable intrinsic properties indicate that antisense-mediated regulation of gene expression must operate through a variety of mechanisms, and further suggest that NATs are a heterogeneous group of regulatory RNAs (25). Yu et al found that leukemia cells had larger amounts of p15 NAT and smaller amounts of p15 mRNA than normal lymphocytes. Furthermore, they demonstrated that an antisense of p15 expression construct induced p15 silencing, which has been frequently observed in leukemia (16) . In addition, Grigoriadis et al (17) reported that differential expressions between normal and malignant breast samples were observed for many sense and antisense pairs. Taking these observations together with our findings that 415 NATs were expressed differentially in CRC and non-cancerous tissues to a significant degree, NATs are strongly indicated to be involved in various types of cancer, including CRC. In the future, a comprehensive investigation should be performed for all types of cancer to obtain NAT catalogs for various cancers and stages of cancers. Such a catalog could be the basis for finding molecular markers of precancerous stages as well as for understanding cancer development.
